Something happened last week that a lot of you have been waiting for, and I want to celebrate it with you.

On July 23 and 24, an FDA advisory committee voted to recommend adding several of the most popular peptides in our space, BPC-157, KPV, TB-500, and MOTS-c, to the list of substances that pharmacies are permitted to compound. For the providers using these tools every day, and for the patients asking for them, that’s a real win.

Your patients want peptides. You’ve seen what they can do. And the door to using them is opening wider. That’s good news for personalized medicine, and I’m right there celebrating it with you.

So this isn’t a note of caution. It’s the opposite. It’s how to get even more out of the tools you’re already excited about.

The conversation has changed, and it’s changing in our favor

For years, the providers doing the most advanced work in medicine have had to push these therapies uphill. Peptides, regenerative protocols, cellular medicine. The science was real, the outcomes were real, and the access lagged behind.

That’s shifting now. Momentum is moving toward the clinicians who think in systems and treat the whole person. Toward the ones who were early, who did the reading, who trusted the mechanism when it wasn’t yet convenient.

That’s you. And after 30-plus years in this field, I can tell you there is nothing more energizing than watching the tools finally catch up to the clinicians.

Now here’s what I taught at SSRP, because it makes your peptides work better

At the SEEDS / Peptide World Congress, I stood in front of a room of some of the most sophisticated clinicians in the country, people already working with peptides, senolytics, exosomes, GLP-1s, and I made one argument. It’s the same one I want to leave you with here, because it’s the thing that turns a good peptide result into a great one.

Peptides amplify signaling. Hormones are the signaling environment.

Think about what your hormones are actually doing. Estradiol regulates receptor sensitivity across the entire body. Testosterone, in men and women, drives tissue repair and muscle protein synthesis. Progesterone governs GABAergic signaling and sleep architecture. Thyroid sets the metabolic floor. Cortisol patterns govern inflammation and recovery.

That’s the environment every peptide is working inside of.

When that hormonal foundation is optimized, your peptides work the way the mechanism promises. The signal is clean, the receptors are responsive, the whole system is primed to do what you’re asking of it. Hormones aren’t another therapy competing for space in your stack. They’re the substrate everything else runs on.

The plateau you’ve felt, and where the answer often is

Here’s the moment I want you to recognize, because almost every advanced provider has lived it.

You run an excellent protocol on a patient who should be responding. Good compliance. Reasonable biomarkers. And they get partway there and stall. Or they respond beautifully for three months and then it fades.

The instinct is to look at what you added. Adjust the peptide. Stack another therapy. Reach for the next tool.

And sometimes that’s right. But very often, the answer isn’t the thing on top. It’s the foundation underneath. When estradiol is low, progesterone is undetectable, and free testosterone is on the floor, even a perfect peptide protocol is being asked to perform in a degraded environment. Optimize the hormones first, and suddenly the same peptide starts delivering what you knew it could.

That’s not a knock on peptides. It’s the highest compliment I can pay them. These tools are powerful enough that they deserve a foundation worthy of them.

Foundation first, then amplify

This is the sequence I want every provider in this movement to internalize:

Optimize the hormonal foundation. Then layer the advanced tools on top of a system that can actually respond.

Comprehensive hormone optimization is not the boring prerequisite you get past on your way to the exciting therapies. It’s what makes the exciting therapies deliver. Reading optimal ranges, not just normal ones. Treating the whole system, adrenals and thyroid and metabolic markers, not one lab value at a time. Understanding how the pieces work together. That’s the foundation. And peptides sitting on top of a strong one is where the real transformation happens.

Bottom line

The FDA opening the door wider on peptides is a genuine win, and I’m celebrating it right alongside you and your patients. Use these tools. Lean in. This is exactly the direction personalized medicine should be moving.

What this means for you: to get the most out of the peptides you’re excited about, make sure the hormonal foundation underneath them is fully optimized. Foundation first, then amplify. That single sequence will change what your patients feel and what your protocols deliver.

That’s the work the BHRT Training Academy was built for: comprehensive, evidence-based hormone mastery with real clinical mentorship, so the advanced work you’re already doing has the foundation it deserves.

The conversation has changed. The tools are catching up. And the providers who pair advanced therapies with an optimized hormonal foundation are going to lead what comes next.

I think that’s you.

Donna White is The Hormone Defender and founder and CEO of the BHRT Training Academy, that trains providers in comprehensive, evidence-based bioidentical hormone care.